



Caris Life Sciences, Inc. **(NYSE: CAI)**

Healthcare & Industrials



Recommendation: Buy | Target Price: \$28.28 | Implied Upside: 48.84%

Mason Brown – Portfolio Manager

Charlie McGee – Associate

Zeena Khalidi – Senior Analyst

Mateo Curak – Junior Analyst

Oliver Tuey – Junior Analyst

Executive Summary Caris Life Sciences Inc. (NYSE: CAI)

Company Overview

- Caris Life Sciences (NYSE: CAI) is a precision oncology company that provides molecular profiling to help guide cancer treatment decisions. Its platform combines DNA, RNA, and protein analysis with AI-enabled interpretation, serving both clinical customers and biopharma partners.
- Our valuation model implies an intrinsic value of **\$28.28 per share**, representing approximately **49% upside** from the **current share price of \$19.00**.

Industry Overview

- Precision oncology is rapidly expanding as falling sequencing costs, rising cancer incidence, and broader reimbursement drive adoption of genomic testing across healthcare.
- The shift toward biomarker-driven therapies and AI-enabled molecular analysis is accelerating demand for integrated genomic platforms that support both clinical decision-making and biopharma research.

Investment Thesis

- Caris is differentiated by its scaled clinical-genomic dataset, integrated multi-omic platform, and growing AI capabilities, which together create a durable competitive moat in precision oncology.
- As adoption of biomarker-driven testing accelerates and the market continues to over-discount MCED-related sentiment, Caris is positioned to benefit from strong operating leverage and multiple expansion as fundamentals improve.

Valuation

- The market currently underestimates Caris' long-term monetization potential, particularly within its core molecular profiling franchise and broader precision oncology platform.
- Our model implies an intrinsic value of \$28.28 per share, or approximately 49% upside relative to the current share price.

Risks & Catalysts

- Caris faces risks from reimbursement execution, regulatory complexity, and competitive pressure as the precision oncology market continues to evolve.
- At the same time, expanding dataset scale, stronger physician adoption, and positive clinical readouts remain important catalysts for testing growth and multiple re-rating.

Recommendations

- We recommend a Buy on Caris with a blended price target of \$28.28 per share.
- This implies approximately 49% upside from the current share price and reflects our view that the market is underappreciating the company's platform scale, operating leverage, and long-term earnings potential.

Caris Life Sciences Inc. (NYSE: CAI)



Company Overview

Industry Overview

Investment Thesis

Valuation

Risks & Catalysts

Recommendation

Caris Life Sciences Inc. (NYSE: CAI)




Caris is a precision oncology platform that combines large-scale multi-omic profiling with AI-enabled interpretation to guide therapy selection and support biopharma research, with rapidly scaling revenue and a clear path toward profitability.

Business Description

- Founded in **2008**; headquartered in **Irving, Texas**
- Provides oncology-focused molecular profiling across **DNA, RNA, and protein** through its clinical platform
- Operates an integrated model spanning lab execution, interpretation, and reporting for oncologists and health systems
- Builds a scaled oncology data asset that supports both clinical decision support and biopharma R&D applications
- Collaborates with **100+ biopharma partners** to support biomarker discovery, clinical trial design, and therapy development

Revenue Segments



- Clinical / Molecular Profiling Services
- Pharma Research & Development Services

Description

Clinical Testing:

Multi-omic profiling used for therapy selection and molecular characterization

Biopharma:

Research services + insights that monetize the dataset beyond diagnostics

Emerging:

Platform expansion opportunities, including blood-based approaches

Management Team



David Dean Halbert



George Poste



Jonathan Knowles

Position

Chairman, Founder and CEO

Vice Chairman

Vice Chairman

Tenure (Years)

17

11

5

Caris' Precision Oncology Ecosystem

Clinical Customers

- **Primary users:** oncologists, pathology labs, and health systems
- **Use case:** therapy selection, molecular characterization, and biomarker interpretation for cancer patients
- **Workflow:** tissue- and blood-based profiling integrated into clinical decision-making
- **Buying motion:** ordered per patient case; revenue primarily driven by clinical molecular profiling services

Biopharma Partners

- **100+** biopharma partners
- **Use case:** biomarker discovery, patient stratification, and trial enablement using real-world molecular + outcomes data
- **Outputs:** insights and services that support drug development across oncology programs
- **Monetization:** research & development services and data-driven insights built on the same underlying platform

Patient Testing



Molecular Data



AI Interpretation



Drug Development Insights

Why the mix matters: One platform, two monetization paths: clinical testing builds the dataset, while biopharma services monetize the same asset, reinforcing a data flywheel over time.

Revenue Drivers




As testing scales, Caris' clinico-genomic dataset expands, strengthening the platform's long-term value.

Revenue Streams

<p>Precision Oncology</p> <p>Growth in targeted cancer therapies requires genetic testing to identify patient-specific mutations.</p>	<p>Testing Growth</p> <p>More oncologists order molecular profiling tests to guide treatment decisions.</p>	<p>Data Expansion</p> <p>Each test adds genomic and clinical outcome data to Caris's platform.</p>	<p>Pharma Revenue</p> <p>Caris data enables biomarker discovery and clinical trials</p>
--	--	---	--

Growing test volumes expand Caris's dataset, increasing its value for physicians and pharmaceutical partners.


Molecular profiling dominates; liquid biopsy emerging



Revenue Quality Metrics

- 94% Clinical Testing** → Diagnostics-driven model (not screening-dependent). Stable, recurring revenue from MI Profile and Caris Assure.
- 66.6% Gross Margin** → Up from 36% in FY24. Fixed cost base absorbs growing test volumes, demonstrating operating leverage.
- \$4,000+ ASP per MI Profile test** → Insurance and Medicare reimbursement support premium pricing for FDA-approved diagnostics.


Caris Clinical-Genomic Dataset Scale



Each test expands Caris' clinico-genomic dataset, strengthening its value for physicians and biopharma partners.

Price to Volume & Key Stats

Price-Volume Chart & Commentary



1

June 18, 2025

Caris IPO, raising capital to scale precision oncology testing platform

2

August 13, 2025

Post-IPO momentum and optimism around genomic testing growth

3

October 17, 2025

Showcases six multi-omics studies at ESMO 2025 in Berlin

4

November 4, 2025

Market-wide pullback; investors rotate out of risky growth names

5

February 19, 2026

NHS-Galleri study misses primary endpoint, pessimism towards MCED

Following a pullback from IPO-driven optimism, Caris has remained under pressure as negative clinical results from a leading competitor dampened investor sentiment across the liquid biopsy and early detection sector.

Key Valuation Metrics

Market Cap	\$5.25B
Share Price	\$18.59
LTM Revenue	\$812M
Revenue Growth	97%
EV	\$4.88B
EBITDA	\$67.7M
Gross Margin	66.6%
Net Income	(\$68.1M)
EV / LTM Revenue	4.86x
EV / EBITDA	62.2x

Caris Life Sciences Inc. (NYSE: CAI)



Company Overview

Industry Overview

Investment Thesis

Valuation

Risks & Catalysts


Recommendation

The Evolution of Oncological Analysis



Falling sequencing costs, expanding reimbursement, and rising cancer incidence have driven the rapid adoption of genomic oncology testing across the healthcare space.

Cancer Analysis Evolution




Targeted Treatments

- **Actionable Treatment Selection:** Tumor sequencing identifies biomarkers that guide therapy decisions, including targeted drugs (ex. EGFR inhibitors), immunotherapy eligibility, chemotherapy response, and clinical trial matching.
- **Matched Therapy Improves Survival:** Patients receiving mutation-matched treatments show significantly better outcomes, including ~2.6x longer median survival compared with non-matched therapy in recent studies.
- **Rapid Clinical Adoption:** Molecular profiling is increasingly integrated into routine oncology care as clinical guidelines expand recommendations for genomic testing to guide treatment decisions.


Oncology is moving from one-size-fits-all chemotherapy toward biomarker-guided targeted solutions; ~43% of oncology drugs approved since 1998 are precision therapies requiring molecular testing, showing a large-scale shift in the industry.

Collapsing Genome Sequencing Costs



While falling sequencing costs made large-scale genomic testing feasible, interpreting millions of genetic variants remained a major bottleneck. AI-driven analysis now enables rapid interpretation of these datasets, accelerating the adoption of precision oncology.

NGS Adoption by Cancer Type



NGS adoption is accelerating across oncology, reinforcing the shift toward biomarker-driven precision medicine.

Broader Trends – Cancer and Healthcare

Rising Cancer Incidence, Genomic Innovation, and Early Detection Are Reshaping Oncology.

Trends in Cancer, Broader Healthcare Technology

Rising Cancer Incidence

- U.S. cancer incidence continues to rise, with ~2.04M new cases projected in 2025 ~2% YoY, driven largely by population aging and increasing diagnoses of cancers such as breast, prostate, pancreatic, and melanoma.

Expanded NGS Reimbursement

- A 2018 Medicare coverage decision began reimbursing next-generation sequencing tests for advanced cancer patients, significantly increasing hospital adoption of genomic profiling to guide treatment decisions.

Scale-Focus in Cancer Analysis


- As sequencing becomes more accessible, competitive advantage is shifting from simply running tests to owning large datasets, AI-driven analytics, client relationships.

Institutional Adoption

- Cancer centers are standardizing molecular profiling across their institutions, integrating genomic testing platforms into treatment and infrastructure workflows.


Rising cancer incidence, reimbursement support for NGS testing, and institutional adoption of molecular profiling are accelerating the shift toward large-scale genomic data platforms in oncology.

U.S. Cancer Incidence



The rise in U.S. cancer incidence is driven both by age and faster growth in women and younger cohorts driven by increases in several major cancers and partly reinforced by improved screening and diagnosis.

Global Cancer Pharmaceutical Development Spending



Early Detection – MCED Technologies

- Emerging Multi-Cancer Early Detection (MCED):** Blood-based genomic screening tests that detect early cancer signals are currently being evaluated in large clinical trials and may significantly expand early detection in oncology.
- Strong Initial Results:** Recent studies demonstrate ~4× higher cancer detection and increased identification of stage I/II cancers compared to conventional screening alone.

Cancer	Stage I Survival Rate	Stage IV Survival Rate
Colorectal	92.3%	18.4%
Lung	81.9%	8.6%
Breast	99.2%	23.4%

U.S. policy tailwinds are supporting these developments, with new legislation passed Feb. 3, 2026 requiring Medicare coverage of FDA-approved MCED tests for individuals aged 50+ beginning in 2029.


Competitive Landscape

Most oncology diagnostics companies specialize in single tests, with few platforms offering integrated genomic data, diagnostics, and clinical decision support.

Competitor	Company Description	Market Cap (\$USD millions)	EV/Revenue
	Molecular diagnostics company focused on cancer screening and early detection tests, including Cologuard and liquid biopsy platforms.	19,756.9	6.6x
	Leading provider of DNA sequencing technology and genomic analysis platforms used across research, diagnostics, and precision medicine.	19,054.4	4.6x
	Genomic diagnostics company specializing in cell-free DNA testing for oncology, prenatal screening, and transplant monitoring.	28,081.2	11.8x
	Biotechnology company developing multi-cancer early detection (MCED) blood tests, including the Galleri screening test.	2,025.8	4.7x
	Precision medicine company leveraging AI and large clinical/genomic datasets to guide cancer diagnostics and therapy selection.	9,342.7	7.8x

Competitive Positioning

Caris Life Sciences and Tempus



Comprehensive tumor profiling with one of the largest matched genomic oncology datasets supporting biomarker discovery, therapy selection.

AI-driven precision medicine platform integrating targeted tumor sequencing with clinical data and physician workflow software tools.

Caris and Tempus Lead the Precision Oncology Platform

Caris and Tempus are the only scaled platforms combining tumor molecular profiling, oncology diagnostics, and integrated clinical decision support capabilities within the precision oncology ecosystem.

While Caris and Tempus both operate integrated precision oncology platforms, Caris' multi-omic sequencing and large molecular dataset strengthen its competitive positioning in oncology profiling and biomarker discovery.

Caris and Tempus represent the only scaled, integrated precision oncology platforms, while peers focus only on single diagnostics or cancer screening.

Caris Life Sciences Inc. (NYSE: CAI)



Company Overview

Industry Overview

Investment Thesis

Valuation

Risks & Catalysts


Recommendation

Thesis (1/3): Durable Economic Moat Built on Clinical-Genomic Scale




Caris' proprietary data scale, oncology-focused platform, and multimodal profiling capabilities position it as one of the best-differentiated players in molecular diagnostics. As clinical utility and biopharma relevance deepen, Caris' competitive advantages should become increasingly difficult to replicate.

Scaled Clinical-Genomic Data Asset



- Caris' data asset is differentiated not only by size, but by the breadth of linked molecular, clinical, and pathology data embedded within a single oncology-focused platform.
- This depth improves the platform's ability to generate clinically relevant insights, support treatment decisions, and strengthen downstream research utility.
- With each additional profile, Caris expands a proprietary dataset that should become increasingly valuable and harder for competitors to replicate over time.

Full-Stack Multimodal Profiling




Proprietary AI Layer Trained on Oncology Data

GPSai AI Insights	Tissue-of-origin	90 categories 95% accuracy 84% CUP resolved
FOLFIRSTai	mCRC sequencing	Clinically validated
AI Insights	Capecitabine response	2,000+ features (Feb 2026)

Investment Implications

- Better decisions:** turns complex multi-omic results into clearer, more actionable treatment insights
- Stickier workflow:** validated tools get embedded in physician use, increasing switching costs over time
- Compounding moat:** more cases feed the models, improving performance and making the AI harder to replicate

Differentiated Platform Converting into Revenue Scale



Gross profit: \$541M (FY25A) → \$678M (FY26E) **Gross margin: 66.6% (FY25A) → 67.5% (FY26E)**


Caris' differentiated platform (data + multi-omic profiling + AI interpretation) is scaling into higher revenue and sustained gross margin expansion, supporting a credible path to operating leverage.

Thesis (2/3): Structural Growth Tailwinds and Scalable Data Platform




As more oncologists adopt Caris's profiling, test volume grows - but the cost base barely moves. Revenue is growing far faster than expenses, and every incremental test drops disproportionate profit to the bottom line.


Precision Oncology Adoption Is Accelerating




Building a Proprietary Oncology Data Asset



- Targeted cancer therapies have expanded significantly over the past two decades, reflecting the shift toward precision oncology.
- As genomic testing becomes the standard of care for selecting these therapies, demand for molecular profiling continues to grow.



Scalable Diagnostics Model Creates Operating Leverage




Thesis (3/3): Market Dislocation from MCED De-Rating



Category-wide de-rating following the NHS-Galleri miss has compressed genomics valuations, creating a mispricing in CAI, whose core revenue is driven by therapy selection and pharma partnerships—not screening.

Market Overreaction to NHS-Galleri Study Preliminary Results

- On February 19, 2026, GRAIL (NYSE: GRAL) released a study in **142,000 asymptomatic adults aged 50-77** in England, testing annual Galleri screening
- Missed primary endpoint: the study did not show a statistically significant reduction in combined **stage III-IV cancers**, creating investor skepticism of MCED technologies



The NHS-Galleri result compresses MCED sentiment across the sector but does not directly impair CAI's core revenue engine.

- ### Different Product Categories

 - Galleri is a multi-cancer early detection (MCED) screening system for asymptomatic adults
 - Caris Assure uses blood-based profiling for therapy selection
 - ~94% of CAI 2025 revenue derived from Molecular Profiling Services, not screening
- ### Caris Detect is Fundamentally Different from Galleri


 - Galleri relies primarily on cfDNA methylation
 - Caris Detect utilizes whole-genome sequencing (WGS) with promising early-stage validation results (Achieve 1 study)
 - Detect remains an early optionality program, it does not provide revenue
- ### Core Business Fundamentals are Unaffected

 - Tissue profiling and therapy-selection liquid biopsy drive current revenue and projected growth
 - Pharma & research revenue growth (2026 guidance: \$~75-85M)
 - Market reaction reflects caution with MCED, which is not a core piece of the Caris' business.


Fundamentals Diverge from Sentiment

	MCED Revenue (Mix)	EBITDA Positive	FCF Positive	Net Cash
CARIS	\$0 (0%)	✓	✓	\$426.2M
EXACT SCIENCES	\$2.53B (~78%)	✓	✓	(\$1.36B)
GRAIL	\$42.3M (~97%)	X	X	\$170.0M

CAI trades at 6.2x EV/Revenue alongside MCED-dependent, unprofitable peers despite having no screening revenue exposure and a materially stronger earnings profile — suggesting category-driven mispricing.



MCED is a Promising Optionality, not the Core Driver of Business



Achieve 1 results show early validation of Caris Detect. By analyzing genome-wide cfDNA alterations and patterns, the platform applies a multi-signal architecture distinct from methylation-only screening assays.

Valuation reflects category sentiment, not underlying revenue drivers, risk factors, or data.



Caris Life Sciences Inc. (NYSE: CAI)



Company Overview

Industry Overview

Investment Thesis

Valuation

Risks & Catalysts

Recommendation

Comparable Company Analysis

CAI trades in line with precision oncology peers at ~6.2x EV/Revenue.

Visualization of Peer Universe

(In USD millions)	Equity Value	Enterprise Value	Revenue			EV/Revenue		
			2024A	2025A	2026E	2024A	2025A	2026E
Cancer Diagnostic and Screening Companies								
GRAIL, Inc.	2,009	1,160	126	247	180	9.2x	4.7x	6.4x
Tempus AI, Inc.	9,353	9,926	693	1,272	1,592	14.3x	7.8x	6.2x
Illumina, Inc.	19,002	19,922	4,372	4,343	4,536	4.6x	4.6x	4.4x
Exact Sciences Corporation	19,797	21,367	2,759	3,247	3,662	7.7x	6.6x	5.8x
Natera, Inc.	29,086	28,224	1,697	2,306	2,671	16.6x	12.2x	10.6x
Median						9.2x	6.6x	6.2x
Caris Life Sciences, Inc.	11,657	4,998	412	812	1,005	12.1x	6.2x	5.0x

Metric	Multiple			Implied Equity Value			Implied Share Price			Implied Return		
	Lower Limit	Median	Upper Limit	Lower Limit	Median	Upper Limit	Lower Limit	Median	Upper Limit	Lower Limit	Median	Upper Limit
EV/Revenue 2024A	4.6x	9.2x	16.6x	2,741	4,669	7,720	\$ 9.70	\$ 16.53	\$ 27.33	-49%	-13%	44%
EV/Revenue 2025A	4.6x	6.6x	12.2x	4,587	6,205	10,800	\$ 16.24	\$ 21.97	\$ 38.23	-15%	16%	101%
EV/Revenue 2026E	4.4x	6.2x	10.6x	5,275	7,126	11,481	\$ 18.67	\$ 25.22	\$ 40.64	-2%	33%	114%
Median							\$ 16.24	\$ 21.97	\$ 38.23	-15%	16%	101%

Key Takeaways

- Comparable companies operate in precision oncology, specifically those generating revenue from tumor profiling or cancer screening diagnostics.
- Caris currently trades at ~5.0x 2026E EV/Revenue, broadly in line with the peer median despite stronger profitability and positive free cash flow.
- Applying peer multiples implies a valuation range of ~\$18-\$40 per share, with the median suggesting meaningful upside to the current price.

Discounted Cash Flow Analysis

Discounted Cash Flow Output Table

Terminal Value - Exit Multiple	
Terminal Year EBITDA	819,377
Exit EV/EBITDA	15.00x
Terminal Value	12,290,662
(+) PV of Terminal Value	7,048,835
(+) Sum of PV of UFCFs	1,088,813
Implied Enterprise Value	8,137,648
Implied Growth Rate	3.50%
% of Implied EV from Terminal Value	151%
Enterprise Value to Equity Value	
Implied Enterprise Value	8,137,648
(-) Net Debt	427,690
Implied Equity Value	8,565,338
Diluted Shares Outstanding	282,526
Implied Share Price	\$30.32
Premium / Discount to Current	63%

WACC	
Equity	4,880,000
Debt	427,690
Cost of Debt	7.00%
Tax Rate	25.00%
D/(D+E)	8.06%
After Tax CoD	5.25%
Risk Free Rate	4.17%
Expected Market Return	10.00%
Market Risk Premium	5.83%
Levered Beta	1.4
E/(D+E)	92%
Cost of Equity	12.33%
WACC	11.76%

Key Assumptions

Summary of Key Assumptions	
<i>(US\$thousands)</i>	
WACC	11.76%
Perpetuity Growth Rate	3.5%
Exit EV/EBITDA	15.0x
Tax Rate	25%
Cash, Cash Equivalence	797,799
Net Debt	378,450
Diluted Shares Outstanding	282,526,097
Current Share Price	\$18.59

Key Takeaways

- Our base case yields an intrinsic share price of \$30.32, a 63% premium to its current share price.
- Perpetuity Growth Method is typically used for mature companies. It does not accurately reflect the growing nature of CAI.
- The selected Exit Multiple of 15x is in line with industry (biotech) averages.
- Assuming modest MI Profile and Caris Assure growth, CAI sees terminal free cash flow of \$576M.
- Please see Appendix for Revenue Build and full Discounted Cash Flow Model.

Sensitivity Table

		WACC						
		8.16%	9.36%	10.56%	11.76%	12.96%	14.16%	15.36%
Exit Multiple	16.5x	\$37.69	\$35.96	\$34.33	\$32.81	\$31.38	\$30.05	\$28.79
	16.0x	\$36.71	\$35.03	\$33.46	\$31.98	\$30.60	\$29.30	\$28.08
	15.5x	\$35.73	\$34.10	\$32.58	\$31.15	\$29.81	\$28.55	\$27.37
	15.0x	\$34.75	\$33.18	\$31.70	\$30.32	\$29.02	\$27.80	\$26.66
	14.5x	\$33.78	\$32.25	\$30.82	\$29.49	\$28.23	\$27.05	\$25.95
	14.0x	\$32.80	\$31.32	\$29.95	\$28.65	\$27.44	\$26.31	\$25.24
	13.5x	\$31.82	\$30.40	\$29.07	\$27.82	\$26.65	\$25.56	\$24.53

Caris Life Sciences Inc. (NYSE: CAI)

Company Overview

Industry Overview

Investment Thesis


Valuation

Recommendation

Risks and Catalysts

Buy With A Price Target Of \$28.28

Indicative Valuation Range



Price Target

Valuation Summary - Price Target

Analysis	Price	Weight
DCF - Perpetuity	\$ 20.04	10%
DCF - Exit Multiple	\$ 30.32	50%
Comps Analysis	\$ 21.97	20%
Analyst Price Targets	\$ 33.60	20%
Weighted Average	\$ 28.28	100.00%



Selected Broker Summary



The Valuation analysis supports a 'Buy' recommendation with a target price of \$28.28, reflecting a 48.84% upside from the current price of \$19.00/share.

Caris Life Sciences Inc. (NYSE: CAI)



Company Overview

Industry Overview

Investment Thesis

Valuation

Recommendation


Risks & Catalysts

Risks & Catalysts


Key Risks

Risk	Mitigation
1 Billing & Collections Issues <ul style="list-style-type: none"> Complex payer billing workflows create claims processing delays and revenue recognition volatility. Scaling test volumes increases reimbursement timing risk and operational billing friction. 	Caris is expanding payer coverage and reimbursement strategy while scaling specialized oncology commercial infrastructure, improving claims navigation and collections.
2 Regulatory Landscape <ul style="list-style-type: none"> Diagnostic labs operate under extensive healthcare regulations and compliance obligations. Non-compliance could trigger sanctions, fines, operational disruption, or reputational damage. 	Caris operates CLIA-certified laboratories and FDA-approved diagnostic solutions, providing established regulatory infrastructure and experience navigating approvals.
3 Poor Clinical Performance <ul style="list-style-type: none"> New diagnostic launches require clinical validation and regulatory evidence to drive adoption. Weak validation results could delay launches, reimbursement approval, or physician uptake. 	Caris leverages 1M+ molecular profiles, matched clinical outcomes data, and the Precision Oncology Alliance research network to support validation, clinical evidence generation.
4 Competitive Oncology Market <ul style="list-style-type: none"> Precision oncology diagnostics market is rapidly evolving with strong competitive innovation. New technologies or lower-cost sequencing platforms could pressure pricing, market share. 	Caris' platform integrates multi-omic sequencing, AI/ML analytics, and one of the largest genomic oncology datasets, creating a data-driven competitive moat.

Risk Likelihood-Impact Matrix



Catalysts



Caris' expanding dataset, growing physician adoption, and positive MCED trial results position the platform for sustained testing volume and future growth.

Appendix – Revenue Projections

(US\$m) Period	Historicals			Forecast Period				
	2023A	2024A	2025A	2026E	2027E	2028E	2029E	2030E
				1	2	3	4	5
Total Revenue	306128	412260	812033	1,019,004	1,216,512	1,428,667	1,661,089	1,922,149
Molecular Profiling Services	278748	349,115	766,719	939,827	1,113,779	1,302,660	1,511,691	1,749,065
MI Profile (Tissue)		316,656	681,200	829,702	963,698	1,099,869	1,244,172	1,382,275
Cases		146,600	170,300	197,548	227,180	256,714	287,519	316,271
YoY (%)			16%	16%	15%	13%	12%	10%
ASP		\$ 2.16	\$ 4.00	\$ 4.20	\$ 4.24	\$ 4.28	\$ 4.33	\$ 4.37
YoY (%)			85%	5%	1%	1%	1%	1%
Caris Assure (Liquid Biopsy)		32,500	85,550	105,125	139,080	178,591	214,279	249,662
Cases		16,250	29,000	42,050	56,768	73,798	90,033	106,239
YoY (%)			78%	45%	35%	30%	22%	18%
ASP		\$ 2.00	\$ 2.95	\$ 2.50	\$ 2.45	\$ 2.42	\$ 2.38	\$ 2.35
YoY (%)			48%	-15%	-2%	-1%	-2%	-1%
Future Clinical Platforms		0	0	5000	11000	24200	53240	117128
YoY (%)				0%	120%	120%	120%	120%
Pharma and R&D Services	27380	63145	45314	79,177	102,733	126,007	149,398	173,084
Services	21580	46945	33914	60,367	75,459	90,550	106,849	122,877
YoY (%)		118%	-28%	78%	25%	20%	18%	15%
Data Licensing/Collaboration	5800	16200	11400	18,810	27,275	35,457	42,548	50,207
YoY (%)		179%	-30%	65%	45%	30%	20%	18%

Appendix – Discount Cash Flow

(US\$thousands) Period	Historicals			Forecast Period				
	2023A	2024A	2025A	2026E	2027E	2028E	2029E	2030E
				1	2	3	4	5
Revenue	306,128	412,260	812,033	1,019,004	1,216,512	1,428,667	1,661,089	1,922,149
Growth Rate (%)		34.7%	97.0%	25.5%	19.4%	17.4%	16.3%	15.7%
(-) COGS	(625,679)	(669,382)	(766,920)	(845,109)	(910,630)	(974,154)	(1,037,546)	(1,102,771)
EBITDA	(319,551)	(257,122)	45,113	173,895	305,882	454,513	623,542	819,377
Margin (%)	-104.4%	-62.4%	5.6%	17.1%	25.1%	31.8%	37.5%	42.6%
(-) Depreciation & Amortization	(105,792)	(48,913)	(22,615)	(25,475)	(30,413)	(35,717)	(41,527)	(48,054)
margin, % revenue	34.6%	11.9%	2.8%	2.5%	2.5%	2.5%	2.5%	2.5%
EBIT (Operating Income)	(425,343)	(306,035)	22,498	148,420	275,469	418,796	582,015	771,324
Margin (%)	-138.9%	-74.2%	2.8%	14.6%	22.6%	29.3%	35.0%	40.1%
(-) Taxes	-	-	-	(37,105)	(68,867)	(104,699)	(145,504)	(192,831)
Tax Rate (%)	0.0%	0.0%	0.0%	25.0%	25.0%	25.0%	25.0%	25.0%
Net Operating Profit After Tax (NOPAT)	(425,343)	(306,035)	22,498	111,315	206,602	314,097	436,511	578,493
(+) Depreciation & Amortization	105,792	48,913	22,615	25,475	30,413	35,717	41,527	48,054
Growth Rate (%)		-54%	-54%	12.6%	19.4%	17.4%	16.3%	15.7%
Margin (%)	35%	12%	3%	2.5%	2.5%	2.5%	2.5%	2.5%
(+ / -) Change in NWC	(30,700)	(33,100)	(29,100)	(16,558)	(15,801)	(16,972)	(18,594)	(20,885)
Growth Rate (%)		8%	-12%	-76%	-5%	7%	9%	11%
Margin (%)	0%	8%	4%	2%	1%	1%	1%	1%
(-) Capital Expenditures	(12,240)	(8,400)	(16,300)	(15,285)	(18,248)	(21,430)	(24,916)	(28,832)
Growth Rate (%)		-31%	94%	-3%	-2%	-2%	-2%	-2%
Margin (%)	4%	2%	2%	2%	2%	2%	2%	2%
Unlevered Free Cash Flow (UFCF)	(362,491)	(298,622)	(287)	104,947	202,966	311,411	434,529	576,830
Growth Rate (%)		10%	16%	-36667%	93%	53%	40%	33%
WACC (%)				11.76%	11.76%	11.76%	11.76%	11.76%
Present Value UFCF				93,903	162,495	223,079	278,517	330,818
Sum of Present Value UFCF			1,088,813					